Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

Recent & Breaking News (NDAQ:PMN)

ProMIS Shows Potential Against Competing Alzheimer’s Treatments

Stockhouse Editorial August 21, 2018

New Alzheimer’s Treatment Has Promise Above Other Therapies

Featured Press Release August 21, 2018

ProMIS Neurosciences Oligomer Selective Antibody Therapeutic for Alzheimer's Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies in Clinical Development

Canada NewsWire August 21, 2018

ProMIS Releases Q2 2018 Results

Stockhouse Editorial August 14, 2018

ProMIS Neurosciences Announces Second Quarter 2018 Results

Canada NewsWire August 14, 2018

ProMIS Highlights Lessons Learned From AAIC 2018

Stockhouse Editorial August 7, 2018

ProMIS Neurosciences Issues Narrated Commentary on Key Learnings from AAIC 2018

Canada NewsWire August 7, 2018

ProMIS Neurosciences Issues White Paper Entitled 'State of the Art at AAIC 2018'

Canada NewsWire July 31, 2018

ProMIS Neurosciences to Present Preclinical Data on Alzheimer's Disease Therapeutic Antibody PMN310 at Alzheimer's Association International Conference

Canada NewsWire July 10, 2018

ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders

PR Newswire June 28, 2018

ProMIS Neurosciences Unique Discovery Platform Generates Potential New Antibody Therapeutics for Neurodegenerative Diseases

Canada NewsWire June 26, 2018

ProMIS Neurosciences Inc., Treating the Root Cause of Alzheimer's, CEO Clip Video

Newsfile June 25, 2018

ProMIS Neurosciences Reminds Shareholders of June 25th Voting Cut-Off for Upcoming Annual General Meeting

PR Newswire June 20, 2018

ProMIS Neurosciences Initiates Manufacturing of PMN310, its Lead Therapeutic Antibody for Treatment of Alzheimer's Disease

Canada NewsWire June 12, 2018

ProMIS Neurosciences Announces First Quarter 2018 Results

Canada NewsWire May 11, 2018

ProMIS Neurosciences Closes $7.2 Million Private Placement

Canada NewsWire May 1, 2018

ProMIS Neurosciences Announces Publication of Peer Reviewed Scientific Paper Describing a Novel Target on Toxic Oligomers of Amyloid Beta in Alzheimer's Disease

Canada NewsWire April 10, 2018

ProMIS Neurosciences Announces Appointment of Ernest Bush as Head of Pharmacology/Toxicology and Russell Blacher as Head of Manufacturing

Canada NewsWire April 3, 2018

ProMIS Neurosciences Appoints Dr. Sharon Cohen to Scientific Advisory Board

Canada NewsWire March 20, 2018

ProMIS Neurosciences to Present at Upcoming Investor Conferences

Canada NewsWire March 15, 2018